# Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection

> **NCT04366830** · — · NO_LONGER_AVAILABLE · sponsor: **Mesoblast International Sàrl**

## Conditions studied

- Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19

## Interventions

- **DRUG:** Remestemcel-L

## Key facts

- **NCT ID:** NCT04366830
- **Lead sponsor:** Mesoblast International Sàrl
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2021-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04366830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04366830, "Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04366830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*